Skip to content
Screener

Alkermes ALKS Other income, net (Note 6)

Other income, net (Note 6) at other companies

AbbVie logo
AbbVieABBV
$1.48B+156%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
-$127K+54.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$987K+868%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$3.01M+221%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$24.23M-28,279%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.11B+85.1%
Enterprise value$9.18B+133%
P/E122.7×+110×
P/S4.9×+2.0×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
OTHER (EXPENSE) INCOME, NET:
Interest income5,34411,09013,88321,231
Interest expense(25,925)(46,817)
Other (expense) income, net352771(941)2,327
Total other (expense) income, net(20,229)11,861(33,875)23,558
(LOSS) INCOME BEFORE INCOME TAXES(1,876)104,839(63,802)130,328
INCOME TAX PROVISION (BENEFIT)(2,377)17,7412,17720,766
NET (LOSS) INCOME$501$87,098$(65,979)$109,562

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's other income, net (note 6)?
Alkermes (ALKS) reported other income, net (note 6) of $352K in Q2 2026.
How has Alkermes's other income, net (note 6) changed year-over-year?
Alkermes's other income, net (note 6) decreased by 54.3% year-over-year, from $771K to $352K.
What is the long-term trend for Alkermes's other income, net (note 6)?
Over 3 years (2021 to 2025), Alkermes's other income, net (note 6) has grown at a 173.2% compound annual growth rate (CAGR), from $219K to $4.47M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Alkermes's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude